Skip to main content

Advertisement

Log in

Correlation of post-contrast T1-weighted MRI surface regularity, tumor bulk, and necrotic volume with Ki67 and p53 in glioblastomas

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Purpose

p53 and Ki67 status can be relevant to the management of glioblastoma. The goal of this study is to determine whether tumor morphology and bulk depicted on MRI correlate with p53 and Ki67 in glioblastoma.

Methods

A retrospective review of 223 patients with glioblastoma and corresponding p53 or Ki67 status, along with T1-weighted post-contrast MR images was performed. Enhancing tumors were outlined for determining surface regularity, tumor bulk, and necrotic volume. The median value of 0.1 was chosen for p53 and 0.2 for Ki67 to separate each data set into two classes. T tests and receiver operating characteristic analysis were performed to determine the separation of the classes and the predicting power of each feature.

Results

There were significant differences between tumor surface regularity (p = 0.01) and necrotic volume (p = 0.0429) according to Ki67 levels, although neither had statistically significant predictive power (AUC = 0.697, p = 0.0506 and AUC = 0.577, p = 0.164, respectively). There were also significant differences between tumor bulk (p = 0.0239) and necrotic volume (p = 0.0200) according to p53 levels, but again no significant predictive power was found using ROC analysis (AUC = 0.5882, p = 0.0894 and AUC = 0.567, p = 0.155, respectively).

Conclusion

Quantitative morphological tumor characteristics on post-contrast T1-weighted MRI can to a certain degree provide insights regarding Ki67 and p53 status in patients with glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Olar A, Aldape KD (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165–177

    Article  PubMed  PubMed Central  Google Scholar 

  2. Touat M, Idbaih A, Sanson M, Ligon KL (2017) Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 28:1457–1472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bosnyák E, Michelhaugh SK, Klinger NV, Kamson DO, Barger GR, Mittal S, Juhász C (2017) Prognostic molecular and imaging biomarkers in primary glioblastoma. Clin Nucl Med 42:341–347

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zhang Y, Dube C, Gibert M Jr (2018) The p53 pathway in glioblastoma. Cancers (Basel)10 pii: E297

  5. England B, Huang T, Karsy M (2013) Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34:2063–2074

    Article  CAS  PubMed  Google Scholar 

  6. Schröder R, Feisel KD, Ernestus RI (2002) Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas. J Neuro-Oncol 56:127–132

    Article  Google Scholar 

  7. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504–1513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Pérez-Beteta J, Molina-García D, Ortiz-Alhambra JA, Fernández-Romero A, Luque B, Arregui E, Calvo M, Borrás JM, Meléndez B, Rodríguez de Lope Á, Moreno de la Presa R, Iglesias Bayo L, Barcia JA, Martino J, Velásquez C, Asenjo B, Benavides M, Herruzo I, Revert A, Arana E, Pérez-García VM (2018) Tumor surface regularity at MR imaging predicts survival and response to surgery in patients with glioblastoma. Radiology 288:218–225

    Article  PubMed  Google Scholar 

  9. Grossmann P, Gutman DA, Dunn WD Jr, Holder CA, Aerts HJ (2016) Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in glioblastoma. cBMC Cancer 16:611

    Article  CAS  Google Scholar 

  10. Dechristé G, Fehrenbach J, Griseti E, Lobjois V, Poignard C (2018) Viscoelastic modeling of the fusion of multicellular tumor spheroids in growth phase. J Theor Biol 454:102–109

    Article  PubMed  Google Scholar 

  11. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17:98–110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Balogh GA, Mailo D, Nardi H et al (2010) Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients. Exp Ther Med 1:357–361

    Article  PubMed  PubMed Central  Google Scholar 

  13. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncol 27:65–73

    Article  CAS  Google Scholar 

  14. Rios Velazquez E, Meier R, Dunn WD Jr et al (2015) Fully automatic GBM segmentation in the TCGA-GBM dataset: prognosis and correlation with VASARI features. Sci Rep 5:16822

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel Thomas Ginat.

Ethics declarations

Funding

This work is supported, in part, by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Grant no. T32 EB002103.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this type of study formal consent is not required.

Informed consent

For this type of study formal consent is not required.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hasse, A., Dapash, M., Jeong, Y. et al. Correlation of post-contrast T1-weighted MRI surface regularity, tumor bulk, and necrotic volume with Ki67 and p53 in glioblastomas. Neuroradiology 61, 861–867 (2019). https://doi.org/10.1007/s00234-019-02204-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-019-02204-1

Keywords

Navigation